Du er her: Forside > Oslo Axess - Unoterte - Warrants - Derivater > Targovax
Targovax
driller
02.03.2017 15:00
#10500

Ingen grunn til å selge her, denne kan komme til å følge NANO sin kursutvikling.
Stockamateur
03.03.2017 10:06
#11670

Brudd opp i TRVX. I ATH lende. Faktisk et lite gap fra i går også... Litt tynt volum foreløbig til å kvalifisere for breakaway. Tok sjansen likevel og kjøpte (30% av portis) rett under 28. Stopp noe under 26.

Er ellers ca. 50% i cash i påvente av korreksjon i statene.
VetIkke123
03.03.2017 12:07
#45

Stockamateur: Er 31,9 motstand til Trxv ellers?
Stockamateur
03.03.2017 13:18
#11674

Ikke noe definert motstand når aksjen er i ATH.
VetIkke123
03.03.2017 13:26
#46

Det er greit. Lukte EMI ellers?
Stockamateur
03.03.2017 13:55
#11675

En emisjon lurer alltid i kulissene når børsmyggene tar av.
driller
03.03.2017 14:38
#10502

En emisjon rundt 30 kroner vil være veldig gode nyheter. Men det kan hende de venter til mer data er presentert senere i år.
NetromO
04.03.2017 12:18
#13005

De venter med emisjon til kursen er over 50. En 10%'er gir da nok cash.
driller
06.03.2017 07:42
#10503

06/03-2017 07:00:12: (TRVX.OAX) Targovax to present at upcoming conferences

Oslo, Norway, 6 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:

10th European Life Science CEO Forum (hosted by Sachs Associates)

Date: 7 March 2017

Venue: Hilton Zurich Airport Hotel, Zurich, Switzerland

Panel discussion time: 11:10 CET - Advances in Immuno-Oncology Therapeutics Panel

- Magnus Jäderberg (CMO)

Presentation time: 12:25 CET

- Øystein Soug (CEO)

Redeye - Fight Cancer Seminar

Date: 10 March 2017

Venue: Redeye, Stockholm, Sweden

Presentation time: 10:50 CET

Participants: Øystein Soug (CEO)

11th Annual BIO-Equity Spring 2017 Conference

Date: 20-22 March 2017

Venue: CCIB Convention Centre in Barcelona, Spain
Participants: Øystein Soug (CEO) and Peter Skorpil (VP Business Development)

The presentations will be available to download at www.targovax.com following these events.
Stockamateur
06.03.2017 10:13
#11678

Solgte 50% og trailet stopp på resten til 31,50.
Stockamateur
08.03.2017 11:18
#11688

Helt ute nå m.a.o.
NetromO
15.03.2017 07:55
#13008

Last updated 13.03.2017

HANDELSBANKEN STOCKHOLM CLIENTS AC 11,155,584 41.56% 26.44% Nom. SWE
RADIUMHOSPITALETS 4,077,255 15.19% 9.66% Comp. NOR
NORDNET LIVSFORSIKRING AS 1,292,231 4.81% 3.06% Comp. NOR
VPF NORDEA AVKASTNING 1,196,582 4.46% 2.84% Comp. NOR
VPF NORDEA KAPITAL 1,046,754 3.90% 2.48% Comp. NOR
KLP AKSJENORGE 1,000,000 3.73% 2.37% Comp. NOR
DANSKE BANK A/S 743,167 2.77% 1.76% Nom. DNK
TIMMUNO AS 724,650 2.70% 1.72% Comp. NOR
PRIETA AS 720,000 2.68% 1.71% Comp. NOR
KOMMUNAL LANDSPENSJONSKASSE 703,333 2.62% 1.67% Comp. NOR
STATOIL PENSJON 668,916 2.49% 1.59% Comp. NOR
NORDNET BANK AB 622,620 2.32% 1.48% Nom. SWE
PORTIA AS 500,000 1.86% 1.18% Comp. NOR
CRESSIDA AS 470,000 1.75% 1.11% Comp. NOR
NORDEA 1 SICAV 407,168 1.52% 0.96% Comp. LUX
VERDIPAPIRFONDET NORDEA NORGE PLUS 395,903 1.47% 0.94% Comp. NOR
SUNDT AS 300,000 1.12% 0.71% Comp. NOR
VIOLA AS 300,000 1.12% 0.71% Comp. NOR
THORENDAHL INVEST AS 260,000 0.97% 0.62% Comp. NOR
AVANZA BANK AB 258,796 0.96% 0.61% Nom. SWE
Total number owned by top 20 26,842,959 100% 63.61%
Total number of shares 42,199,719 100%
driller
17.03.2017 12:13
#10506

17/03-2017 12:10:41: (TRVX.OAX) Targovax ASA applies for transfer to Oslo Stock Exchange main list

The board of directors of Targovax ASA has resolved to send an application to transfer the listing of the company's shares from Oslo Axess to Oslo Stock Exchange main list. The application will be sent to Oslo Stock Exchange today, 17 March 2017.

For further information, please contact:

Renate Birkeli, Investor Relations
driller
11.05.2017 19:41
#10514

For de som ikke har tittet på dette selskapet vil jeg anbefale å bruke noen minutter på å lese seg opp. Det ellers utskjelte Hegnar Forum har enkelte veldig informative innlegg om selskapet (innimellom all støyen som er på det forumet). Om noen dager kunngjøres abstract for presentasjonen på American Society of Clinical Oncology sin årskonferanse i Chicago som starter 2. juni. Selskapet har såpass selvtillit når det gjelder hva de har å presentere at de allerede har kunngjort Capital market updates i Oslo 8. juni og i London 26. juni. Som med NANO er dette selvsagt ikke noe banker for de som vil unngå risiko men potensialet overstiger nok fantasien til de fleste :-)
driller
18.05.2017 16:42
#10515

Håper flere her får opp øynene for dette spennende selskapet etterhvert. Kan komme til å «ta en NANO» snart. JPM forøvrig største kjøper i dag.

Endret 18.05.2017 16:50 av driller
NetromO
18.05.2017 17:03
#13010

Absolutt spennende. Har vært ut og inn i denne fra kr 10. Mest inne :)

Doblet i dag på basis av abstractet. Mange utenlandske meglerhus på kjøpern.
driller
18.05.2017 18:38
#10516

Hyggelig å høre Morten, jeg sitter også med både TRVX og NANO, og har stor tro på at begge vil stige til noen hundre kroner etterhvert.
driller
22.05.2017 21:14
#10517

Har plukket litt mer TRVX etter den fine meldingen forrige uke, trader ikke men legger de i skuffen. Tror dette blir en god investering på 1-2 års sikt.
driller
06.06.2017 07:28
#10518

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that it presented clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in a poster presentation at the American Society of Clinical Oncology Annual Meeting 2017 (ASCO) on Saturday, June 3rd 2017.

The study evaluated safety, immunological response and overall survival of TG01/GM-CSF and gemcitabine as an adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas. The data show that:

TG01/GM-CSF generated early immune responses in 89% of patients (17/19) with resected pancreatic cancer. 95% of patients (18/19) showed immune activation in either DTH and/or PBMC tests. This demonstrates that TG01 vaccination activates mutant RAS specific T cells
Overall survival was encouraging in view of published reports with a median overall survival of 33.1 months
The regimen was generally well tolerated although some late, manageable allergic reactions were seen
Magnus Jaderberg MD, Chief Medical Officer of Targovax, said, "These data provide support of TG01-immunotherapy for the treatment of resected pancreatic cancer. This is a key milestone for Targovax and we look forward to defining the next step in development for this combination therapy. Targovax is also evaluating TG02, the second TG cancer immune activator, in colorectal cancer. We recently announced the initiation of this phase Ib trial, and the readout expected in the second half of 2018 will provide important mechanistic data, not just for TG02, but for the entire TG technology platform."
NetromO
06.06.2017 07:37
#13015

God bekreftelse. Når skal DNB øke LOA?

yemaya 2
06.06.2017 08:42
#8413

TRVX burde vel rykke opp til pitten.
driller
08.06.2017 17:00
#10519

Oslo, 8 June 2017: Targovax ASA ("Targovax" or the "Company") has retained ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA (the "Managers") to advise on and effect a contemplated private placement of new shares directed towards Norwegian and international investors with gross proceeds of approximately NOK 175 - 225 million (the "Private Placement").

The net proceeds from the Private Placement will be used to finance five additional data read-outs from clinical trials through 2018, in addition to the three planned data-read outs in H2 2017, and selective CMC development in preparation for future pivotal clinical studies. The Company's two largest shareholders HealthCap and the Norwegian Radium Hospital Research Foundation have indicated that they will subscribe for up to NOK 25 million and NOK 5 million, respectively, in the Private Placement.

The subscription price in the Private Placement will be determined through an accelerated bookbuilding process. The minimum subscription and allocation in the Private Placement has been set to the number of new shares that equals an aggregate subscription price of at least the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, offer and allocate an amount below EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations are available.
________________________________________
Antall aksjer øker med dette fra ca 42 mill til ca 50 mill, og selskapet er sikret finansiering av både nåværende og nye tester de neste to årene. Jeg tror dette er riktig, ikke minst for å få økt fokus fra de to meglerhusene.
VetIkke123
09.06.2017 08:19
#58

Trvx gjør en PCIB snart ellers?
Harry
12.06.2017 21:22
#6878

Det kommer en reparasjonsemisjon på NOK 40m som vil være åpen for tegning 3-14. juli. Tegningsretter vii henhold til eierliste per 8. juni 2017. God aften fra Harry.

Endret 12.06.2017 21:22 av Harry
yemaya 2
12.06.2017 22:00
#8443

TRVX er i pitten nå Harry.
Varsling på tema     Varsling på stikkord




StockTalk er en tjeneste levert av Kreateam Consult AS. Orgnr. 911 839 806 MVA
Adresse: Postboks 39 Holmlia, 1201 Oslo. Email: st@stocktalk.no Tlf. 40 07 31 70
Kontakt oss | Hjelp | Regler | Sett som startside | Legg til favoritter